EMA Recommends Granting a Marketing Authorisation for Vimseltinib By Ogkologos - September 5, 2025 116 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults with symptomatic tenosynovial giant cell tumour Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Trastuzumab Deruxtecan Shows Antitumour Activity and Durable Responses in Heavily Pretreated... May 16, 2024 7 ways we’ve influenced progress in lung cancer November 1, 2022 Cancer-Free Bell Broken by Excited Patient Who Just Got Done Battling... July 17, 2019 Being Diagnosed With a Childhood Cancer As an Adult Led Me... May 18, 2023 Load more HOT NEWS This Common Antibiotic May Help Support Immune System in Cancer Patients... Girl’s New College Dorm Has Perfect View Of The Hospital Room... Perioperative Treatment with Nivolumab Results in Significantly Longer Event-Free Survival than... Breast Cancer Survivor is Swimming the English Channel to Benefit Mental...
